Zhong, Chunge http://orcid.org/0009-0000-7017-7459
Jiang, Wen-Jie http://orcid.org/0009-0009-9678-9889
Yao, Yingjia
Li, Zexu http://orcid.org/0000-0002-4685-4656
Li, You
Wang, Shengnan
Wang, Xiaofeng
Zhu, Wenjuan
Wu, Siqi
Wang, Jing
Fan, Shuangshuang
Ma, Shixin
Liu, Yeshu
Zhang, Han
Zhao, Wenchang
Zhao, Lu
Feng, Yi
Li, Zihan http://orcid.org/0000-0001-5082-9560
Guo, Ruifang
Yu, Li
Pei, Fengyun
Hu, Jun
Feng, Xingzhi
Yang, Zihuan http://orcid.org/0000-0002-0244-3214
Yang, Zhengjia
Yang, Xueying
Hou, Yue http://orcid.org/0000-0002-5040-9344
Zhang, Danni
Xu, Dake http://orcid.org/0000-0003-0931-7189
Sheng, Ren http://orcid.org/0000-0002-2293-8986
Li, Yihao
Liu, Lijun
Wu, Hua-Jun http://orcid.org/0000-0003-3498-3095
Huang, Jun
Fei, Teng http://orcid.org/0000-0001-9620-0450
Article History
Received: 17 January 2023
Accepted: 17 June 2024
First Online: 29 June 2024
Competing interests
: A patent application has been filed through Northeastern University with T.F., C.Z., and Z.L. listed as co-inventors regarding targeting PLK4 in oxaliplatin-resistant cancers. Y.L. is an employee of BeiGene. All other authors declare no competing interests.